WHAT IS CLAIMED IS

1. A phenoxypropylamine compound of the formula (I)



(I)

wherein each symbol in the formula means as follows:

a bond represented by a solid line and a dotted line shows a double bond or a single bond;

X is a hydrogen atom, a hydroxy group, a C_1-C_8 alkoxy group, an acyloxy group or an oxo group;

provided that when R^1 is a group of the following formula (2), X should not be a hydrogen atom;

R^1 is a group of the following formula



(1) (2)



(3) or (4)

wherein

Y is O or S,

Ar is optionally substituted aromatic hydrocarbon,

R^2 is optionally substituted aryl group or optionally substituted aromatic heterocyclic group,

R^5 is optionally substituted aryl group or optionally substituted aromatic heterocyclic group,

Z is void or $-CH_2-$, and

R^6 is hydrogen atom, hydroxy group, acetamido group, carboxyl group, alkoxycarbonyl group, cyano group or C_1-C_8 alkoxy group;

R^3 is a hydrogen atom, a C_1-C_{18} alkyl group or a halogen atom;

V is $-CH_2-$, $-O-$, $-S-$ or the formula $-N(R^4)-$ wherein R^4 is hydrogen atom, C_1-C_{18} alkyl group or optionally substituted aralkyl group;

W is void or $-CH_2-$ or $-C(=O)-$;

R^7 is a C_1-C_4 hydroxyalkyl group, an acyl group, an optionally substituted saturated or unsaturated heterocyclic group, an optionally substituted fused heterocyclic group, a C_1-C_4 alkylsulfonyl group or the formula $-Q-R^9$

wherein

Q is $-C(=O)-$, $-C(=S)-$, $-CH_2-$ or $-S(=O)_2-$, and

R^9 is a group of the following formula

(5)

(6)



(7)



(8)



(9)



(10)



(11)



(12)



(13)

or $-NH-NH-R^{15}$

wherein R^{10} and R^{11} are each independently hydrogen atom, C_1-C_{18} alkyl group, optionally substituted aryl group, optionally substituted aralkyl group or alkoxy group, R^{12} is hydrogen atom, optionally substituted aryl group, C_1-C_{18} alkyl group, C_1-C_8 alkoxy group or acyl group, and R^{15} is hydrogen atom, phenyl group, C_1-C_4 alkyl group, C_1-C_2 halogenated alkyl group, halogen atom, C_2-C_4

alkenyl group, C_1–C_4 hydroxyalkyl group, alkoxyalkyl group, alkyloxycarbonyl group, optionally substituted amino group, acetamido group, carboxyl group, acyl group, optionally substituted alkyloxy group, alkylthio group or cyano group;

provided that when R^1 is a group of the above formula (2), R^7 should not be C_1–C_4 hydroxyalkyl group or acyl group, and R^{10} and R^{11} are not each hydrogen atom at the same time; or

R^7 and W in combination may form a ring of the following formula

(14)

wherein

E is oxygen atom or sulfur atom, and

Q' is an optionally substituted 4 to 7-membered heterocycle having 1 or 2 hetero atom(s) selected from the group consisting of nitrogen atom and oxygen atom in the ring, in which case V is hydrogen atom; and

Ra, Rb and Rc are each independently a hydrogen atom, a C_1–C_{18} alkyl group, a hydroxy group, a C_1–C_8 alkoxy group, a halogen atom, an acyl group, a nitro group or an amino group;

provided that when R^7 and W are bonded to form a ring of the above formula (14), Ra, Rb and Rc are not each hydroxy group or C_1–C_8 alkoxy group;

an optically active compound thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

2. The compound of claim 1, which is represented by the formula (I)



(I)

wherein each symbol in the formula means as follows:

a bond represented by a solid line and a dotted line shows a double bond;

X is a hydrogen atom, a hydroxy group, a C_1–C_8 alkoxy group, an acyloxy group or an oxo group;

R^1 is a group of the following formula



(1) (2) (3) or (4)

wherein

Y is O or S,

Ar is optionally substituted benzene or naphthalene,

R^2 is optionally substituted aryl group or optionally substituted aromatic heterocyclic group,

R^5 is optionally substituted aryl group or optionally substituted aromatic heterocyclic group,

Z is void or $-CH_2-$, and

R^6 is hydrogen atom, hydroxy group, acetamido group, carboxyl group, alkoxycarbonyl group, cyano group or C_1–C_8 alkoxy group;

R^3 is a hydrogen atom, a C_1–C_{18} alkyl group or a halogen atom;

V is $-CH_2-$, $-O-$, $-S-$ or the formula $-N(R^4)-$ wherein R^4 is hydrogen atom, C_1–C_{18} alkyl group or optionally substituted aralkyl group;

W is void or $-CH_2-$ or $-C(=O)-$;

R^7 is a C_1–C_4 hydroxyalkyl group, an acyl group, an optionally substituted saturated or unsaturated heterocyclic group, an optionally substituted fused heterocyclic group, a C_1–C_4 alkylsulfonyl group or the formula $-Q-R^9$

wherein

Q is $-C(=O)-$, $-C(=S)-$, $-CH_2-$ or $-S(=O)_2-$, and

R^9 is a group of the following formula



(5)



(6)



(7)



(8)



(9)



(10)



(11)



(12)



(13)

or $-NH-NH-R^{15}$

wherein R^{10} and R^{11} are each independently hydrogen atom, C_1–C_{18} alkyl group, optionally substituted aryl group, optionally substituted aralkyl group or alkoxy group, R^{12} is hydrogen atom, optionally substituted aryl group, C_1–C_{18} alkyl group, C_1–C_8 alkoxy group or acyl group, and R^{15} is hydrogen atom, phenyl group, C_1–C_4 alkyl group, C_1–C_2 halogenated alkyl group, halogen atom, C_2–C_4 alkenyl group, C_1–C_4 hydroxyalkyl group, alkoxyalkyl group, alkyloxycarbonyl group, optionally substituted amino group, acetamido

group, carboxyl group, acyl group, optionally substituted alkyloxy group, alkylthio group or cyano group; and

Ra, Rb and Rc are each independently a hydrogen atom, a C_1–C_{18} alkyl group, a hydroxy group, a C_1–C_8 alkoxy group, a halogen atom, an acyl group, a nitro group or an amino group;

provided that when R^1 is a group of the above formula (2), R^7 should not be C_1–C_4 hydroxyalkyl group or acyl group, and R^{10} and R^{11} are not each hydrogen atom at the same time;

an optically active compound thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

3. The compound of claim 2, which is represented by the formula (I) wherein each symbol in the formula means as follows:

a bond represented by a solid line and a dotted line shows a double bond;

X is a hydroxy group;

R^1 is a group of the following formula



(3)

or



(4)

wherein

R^5 is optionally substituted phenyl group or naphthyl group,

Z is void, and

R^6 is hydrogen atom;

R^3 is a hydrogen atom or a C_1–C_4 alkyl group;

V is $-CH_2-$, $-O-$, $-S-$ or $-N(R^4)-$

wherein R^4 is hydrogen atom, C_1–C_6 alkyl group or optionally substituted aralkyl group;

W is void;

R^7 is a group of the following formula






(15) (16) (17) (18)

or the formula $-CO-R^9$

wherein

R^8 is hydrogen atom, phenyl group, C_1–C_4 alkyl group, C_1–C_2 halogenated alkyl group, halogen atom, C_2–C_4 alkenyl group, C_1–C_4 hydroxyalkyl group, alkoxyalkyl group, alkyloxycarbonyl group, optionally substituted amino group, acetamido group, carboxyl group, acyl group, optionally substituted alkyloxy group, alkylthio group or cyano group, and

R^9 is a group of the following formula





(5) (6) (7)





(8) (9) or (10)

wherein R^{10} and R^{11} are each independently hydrogen atom, C_1–C_{18} alkyl group, optionally substituted aryl group, optionally substituted aralkyl group or alkoxy group, and R^{12} is hydrogen atom, optionally substituted aryl group, C_1–C_{18} alkyl group, C_1–C_8 alkoxy group or acyl group; and

Ra, Rb and Rc are each a hydrogen atom;

an optically active compound thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

4. The compound of claim 2 or claim 3, which is represented by

the formula (I')



(I')

wherein each symbol is as in claim 2,

an optically active compound thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

5. The compound of claim 2, which is selected from the group consisting of

(1) 1-(4-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)-propyloxy)benzo(b)furan-2-ylcarbonyl)pyrrolidine,

(2) 4-(4-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)-propyloxy)benzo(b)furan-2-ylcarbonyl)morpholine,

(4) 4-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)propyloxy)-N,N-dimethylbenzo(b)furan-2-carboxamide,

(12) 1-(4-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)-propyloxy)benzo(b)thiophen-2-ylcarbonyl)pyrrolidine,

(13) 4-(4-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)-propyloxy)benzo(b)thiophen-2-ylcarbonyl)morpholine,

(15) 4-(2-hydroxy-3-(4-(naphthalen-1-yl)piperidino)propyloxy)-N,N-dimethylbenzo(b)thiophene-2-carboxamide,

(17) 4-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)propyloxy)-N,N-dimethylbenzo(b)thiophene-2-carboxamide,

(20) 4-(7-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)-propyloxy)benzo(b)furan-2-ylcarbonyl)morpholine,

(21) 7-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)propyloxy)-N,N-dimethylbenzo(b)furan-2-carboxamide,

(27) 4-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)propyloxy)-N,N-dimethyl-1H-indole-2-carboxamide,

(30) 4-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)propyloxy)-N,N-dimethyl-1-methylindole-2-carboxamide,

(35) 1-(2-(5-methyl-1,2,4-oxadiazol-3-yl)benzo(b)furan-4-yloxy)-3-(4-(naphthalen-2-yl)piperidino)-2-propanol,

(37) 1-(2-(5-methyl-1,3,4-oxadiazol-2-yl)benzo(b)furan-4-yloxy)-3-(4-(naphthalen-2-yl)piperidino)-2-propanol,

(38) 1-(2-(5-trifluoromethyl-1,3,4-oxadiazol-2-yl)benzo(b)furan-4-yloxy)-3-(4-(naphthalen-2-yl)piperidino)-2-propanol,

(39) 1-(2-(5-methyl-1,3,4-oxadiazol-2-yl)benzo(b)furan-7-yloxy)-3-(4-(naphthalen-2-yl)piperidino)-2-propanol,

(42) 1-(2-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-indole-4-yloxy)-3-(4-(naphthalen-2-yl)piperidino)-2-propanol,

(44) 1-(2-(3-methyl-1,2,4-oxadiazol-5-yl)benzo(b)furan-4-yloxy)-3-(4-(naphthalen-2-yl)piperidino)-2-propanol,

(48) 1-(2-(5-methyloxazol-2-yl)benzo(b)furan-7-yloxy)-3-(4-(naphthalen-2-yl)piperidino)-2-propanol,

(81) 3-(4-(3,4-dichlorophenyl)piperidino)-1-(2-(5-methyloxazol-2-yl)benzo(b)furan-4-yloxy)-2-propanol,

(88) 1-(4-(3,4-dichlorophenyl)piperidino)-3-(2-(5-methyl-1,3,4-oxadiazol-2-yl)benzo(b)furan-4-yloxy)-2-propanol, and

(93) 3-(4-(3,4-dimethylphenyl)piperidino)-1-(2-(5-ethyl-1,3,4-oxadiazol-2-yl)benzo(b)furan-4-yloxy)-2-propanol,

an optically active compound thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

6. The compound of claim 1, which is represented by the formula (I)



(I)

wherein each symbol in the formula means as follows:

a bond represented by a solid line and a dotted line shows a double bond or a single bond;

X is a hydrogen atom, a hydroxy group, a C_1-C_8 alkoxy

group or an acyloxy group;

R^1 is a group of the following formula



(2) (3) or (4)

wherein

R^2 is optionally substituted aryl group or optionally substituted aromatic heterocyclic group,

R^5 is optionally substituted aryl group or optionally substituted aromatic heterocyclic group,

Z is void or $-CH_2-$, and

R^6 is hydrogen atom, hydroxy group or C_1-C_8 alkoxy group;

R^3 is a hydrogen atom, a C_1-C_{18} alkyl group or a halogen atom;

R^7 and W are bonded to form a ring of the following formula

(14)

wherein

E is an oxygen atom or a sulfur atom, and

Q' is an optionally substituted 4 to 7-membered heterocycle having 1 or 2 hetero atom(s) selected from the group consisting of nitrogen atom and oxygen atom in the ring,

and V is hydrogen atom; and

Ra, Rb and Rc are each independently a hydrogen atom, a C_1-C_{18} alkyl group, a halogen atom, an acyl group, a nitro group or an amino group;

an optically active compound thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

7. The compound of claim 6, which is represented by the formula (I) wherein each symbol in the formula means as

follows:

a group of the following formula

(14)

is a group of the following formula



(19)



(20)



(21)

or



(22)

wherein

E is an oxygen atom or a sulfur atom,

q is 0, 1, 2 or 3,

$R^{4'}$, $R^{7'}$ and $R^{8'}$ are each independently a hydrogen atom, a C_1–C_{18} alkyl group, an optionally substituted aryl group or an optionally substituted aralkyl group, and

other symbols are as defined in claim 6,

an optically active compound thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

8. The compound of claim 6, which is represented by the formula (I) wherein each symbol in the formula means as follows:

a bond represented by a solid line and a dotted line shows a double bond;

X is a hydroxy group;

R^1 is a group of the following formula



(3)

or



(4)

wherein

R^5 is optionally substituted phenyl group or naphthyl

group,

Z is void, and

R^6 is hydrogen atom;

R^3 is a hydrogen atom or a C_1-C_4 alkyl group;

a group of the following formula

(14)

is a group of the following formula



(19')

wherein q is 1 and $R^{4'}$ is hydrogen atom or C_1-C_4 alkyl group; and

Ra, Rb and Rc are each a hydrogen atom;

an optically active compound thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

9. The compound of claim 6, which is represented by the formula (I")



(I")

wherein each symbol is as as defined in claim 6,

an optically active compound thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

10. The compound of claim 6, which is selected from the group consisting of

(306) 5-(2'-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)-

propyloxy)benzylidene)-1,3-dimethylimidazolidine-2,4-dione,
(307) α-(2'-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)-propyloxy)benzylidene)-γ-butyrolactone,
(308) α-(2'-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)-propyloxy)benzylidene)-γ-butyrolactone,
(309) α-(2'-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)-propyloxy)benzylidene)-γ-butyrolactone,
(310) α-(2'-(3-(4-(3-fluoro-4-methylphenyl)piperidino)-2-hydroxypropyloxy)benzylidene)-γ-butyrolactone,
(311) α-(2'-(3-(4-(3,4-dimethylphenyl)piperidino)-2-hydroxypropyloxy)benzylidene)-γ-butyrolactone,
(312) α-(2'-(3-(4-(4-chloro-3-fluorophenyl)piperidino)-2-hydroxypropyloxy)benzylidene)-γ-butyrolactone,
(313) α-(2'-(3-(4-(4-chloro-3-trifluoromethylphenyl)-piperidino)-2-hydroxypropyloxy)benzylidene)-γ-butyrolactone,
(314) α-(2'-(2-hydroxy-3-(4-(naphthalen-1-yl)piperidino)-propyloxy)benzylidene)-γ-butyrolactone,
(315) α-(2'-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)-propyloxy)benzylidene)-δ-valerolactone,
(316) α-(2'-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)-propyloxy)benzylidene)-γ-valerolactone,
(319) 3-(2'-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)-propyloxy)benzylidene)-2-pyrrolidone,
(322) 3-(2'-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)-propyloxy)benzylidene)-1-methyl-2-pyrrolidone, and
(325) α-(2'-(2-hydroxy-3-(4-(6-methoxynaphthalen-2-yl)piperidino)propyloxy)benzylidene)-γ-butyrolactone,
an optically active compound thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

11. A pharmaceutical agent comprising a compound of claim 1, an optically active compound thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

12. The pharmaceutical agent of claim 11, which is an agent for the treatment of depression.

13. A pharmaceutical composition comprising at least one member selected from the group consisting of a compound of claim 1, an optically active compound thereof, a pharmaceutically acceptable salt thereof and a hydrate thereof, and a pharmaceutically acceptable carrier.

14. The pharmaceutical composition of claim 13, which is an agent for the treatment of depression.

15. A $5HT_{1A}$ antagonist having a selective serotonin reuptake inhibitory action, which comprises a compound of claim 1, an optically active compound thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

16. A selective serotonin reuptake inhibitor having a $5HT_{1A}$ antagonistic action, which comprises a compound of claim 1, an optically active compound thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

17. A compound of the formula (II)



(II)

wherein each symbol in the formula means as follows:

X is a hydrogen atom, a hydroxy group, a C_1–C_8 alkoxy group or an acyloxy group or an oxo group;

R^1 is a group of the following formula





(1) (3) or (4)

wherein

Y is O or S,

Ar is optionally substituted benzene or naphthalene,

R^2 is optionally substituted aryl group or optionally substituted aromatic heterocyclic group,

R^5 is optionally substituted aryl group or optionally substituted aromatic heterocyclic group,

Z is void or $-CH_2-$, and

R^6 is hydrogen atom, hydroxy group, acetamido group, carboxyl group, alkoxycarbonyl group, cyano group or C_1-C_8 alkoxy group,

provided that when V is $-N(R^4)-$, R^6 should not be hydroxy group;

R^3 is a hydrogen atom, a C_1-C_{18} alkyl group or a halogen atom;

V is $-CH_2-$, $-O-$, $-S-$ or the formula $-N(R^4)-$

wherein

R^4 is hydrogen atom, C_1-C_{18} alkyl group or optionally substituted aralkyl group;

W is void, $-CH_2-$ or $-C(=O)-$;

R^{14} is a hydrogen atom or a C_1-C_4 alkyl; and

Ra, Rb and Rc are each independently a hydrogen atom, a C_1-C_{18} alkyl group, a hydroxy group, a C_1-C_8 alkoxy group, a halogen atom, an acyl group, a nitro group or an amino group;

an optically active compound thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

18. A compound of the formula (III)



(III)

wherein each symbol is as follows:

R is an allyl group or a 2,3-epoxypropan-1-yl group;

a bond represented by a solid line and a dotted line shows a double bond or a single bond;

E is an oxygen atom or a sulfur atom;

R^3 is a hydrogen atom, a C_1–C_{18} alkyl group or a halogen atom;

Q' is an optionally substituted 4 to 7-membered heterocycle having 1 or 2 hetero atom(s) selected from the group consisting of nitrogen atom and oxygen atom in the ring; and

Ra, Rb and Rc are each independently a hydrogen atom, a C_1–C_{18} alkyl group, a hydroxy group, a C_1–C_8 alkoxy group, a halogen atom, an acyl group, a nitro group or an amino group;

an optically active compound thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

19. The compound of claim 18, wherein, in the formula (III), each symbol is as follows:

the group of the following formula

(14)

is a group of the following formula



(19) (20) (21) (22)

wherein

E is oxygen atom or sulfur atom,

q is 0, 1, 2 or 3,

$R^{4'}$, $R^{7'}$ and $R^{8'}$ are each independently hydrogen atom, C_1-C_{18} alkyl group, optionally substituted aryl group or optionally substituted aralkyl group, and

other symbols are as defined in claim 18,

an optically active compound thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

20. A compound selected from the group consisting of

2-(4-methoxybenzo(b)furan-2-yl)-5-methyl-1,3,4-oxadiazole,

2-(4-hydroxybenzo(b)furan-2-yl)-5-methyl-1,3,4-oxadiazole,

(S)-2-(4-glycidyloxybenzo(b)furan-2-yl)-5-methyl-1,3,4-oxadiazole,

2-(7-methoxybenzo(b)furan-2-yl)-5-methyl-1,3,4-oxadiazole,

2-(4-(methoxymethyloxy)benzo(b)thiophen-2-yl)-5-methyl-1,3,4-oxadiazole,

2-(4-hydroxybenzo(b)thiophen-2-yl)-5-methyl-1,3,4-oxadiazole,

4-benzyloxy-2-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-indole,

2-(7-methoxybenzo(b)furan-2-yl)-5-phenyl-1,3,4-oxadiazole,

2-(4-methoxybenzo(b)furan-2-yl)-5-trifluoromethyl-1,3,4-oxadiazole,

2-(4-hydroxybenzo(b)furan-2-yl)-5-trifluoromethyl-1,3,4-oxadiazole,

(S)-2-(4-glycidyloxybenzo(b)furan-2-yl)-5-trifluoromethyl-1,3,4-oxadiazole,

2-(7-methoxybenzo(b)furan-2-yl)-5-trifluoromethyl-1,3,4-

oxadiazole,

2-(7-hydroxybenzo(b)furan-2-yl)-5-trifluoromethyl-1,3,4-oxadiazole,

(S)-2-(7-glycidyloxybenzo(b)furan-2-yl)-5-trifluoromethyl-1,3,4-oxadiazole,

N'-(4-methoxybenzo(b)furan-2-ylcarbonyl)propionohydrazide,

2-(4-methoxybenzo(b)furan-2-yl)-5-ethyl-1,3,4-oxadiazole,

2-(4-hydroxybenzo(b)furan-2-yl)-5-ethyl-1,3,4-oxadiazole,

(S)-2-(4-glycidyloxybenzo(b)furan-2-yl)-5-ethyl-1,3,4-oxadiazole,

2-(4-methoxybenzo(b)furan-2-yl)-5-methyl-1,3,4-thiadiazole,

2-(4-hydroxybenzo(b)furan-2-yl)-5-methyl-1,3,4-thiadiazole,

(S)-2-(4-glycidyloxybenzo(b)furan-2-yl)-5-methyl-1,3,4-thiadiazole,

5-ethoxycarbonyl-2-(4-methoxybenzo(b)furan-2-yl)-1,3,4-oxadiazole,

5-ethoxycarbonyl-2-(4-hydroxybenzo(b)furan-2-yl)-1,3,4-oxadiazole,

5-(4-(methoxymethyloxy)benzo(b)furan-2-yl)-2,3-dihydro-1,3,4-oxadiazole-2-thione,

5-(4-(methoxymethyloxy)benzo(b)furan-2-yl)-2-methylthio-1,3,4-oxadiazole,

5-(4-hydroxybenzo(b)furan-2-yl)-2-methylthio-1,3,4-oxadiazole,

5-(4-(methoxymethyloxy)benzo(b)furan-2-yl)-2,3-dihydro-1,3,4-oxadiazol-2-one,

5-(4-(methoxymethyloxy)benzo(b)furan-2-yl)-2-methoxy-1,3,4-oxadiazole,

(S)-5-(4-glycidyloxybenzo(b)furan-2-yl)-2-methoxy-1,3,4-oxadiazole,

2-ethoxy-5-(4-(methoxymethyloxy)benzo(b)furan-2-yl)-1,3,4-oxadiazole,

(S)-2-ethoxy-5-(4-glycidyloxybenzo(b)furan-2-yl)-1,3,4-oxadiazole,

2-(1-methylethyloxy)-5-(4-(methoxymethyloxy)benzo(b)furan-2-

yl)-1,3,4-oxadiazole and

(S)-2-(1-methylethyloxy)-5-(4-glycidyloxybenzo(b)furan-2-yl)-1,3,4-oxadiazole.

5